Literature DB >> 26064301

Association of β2-microglobulin with the prognosis of non-Hodgkin's lymphoma: a meta analysis.

Xiao-Liang Wang1, Xiao-Li Wang1, Shuo He2, Hong-Li Zhai3.   

Abstract

OBJECTIVE: The influence of β2-microglobulin (β2-MG) on the prognosis of non-Hodgkin's lymphoma (NHL) remains controversial. This study performed meta-analyses to evaluate the prognostic value of β2-MG on the overall survival (OS) of NHL.
METHODS: Through a search of relevant literature in PubMed, EMbase, Science Direct, OVID and Wanfang databases from 1980-2013, the hazard ratios (HRs) of OS between the normal β2-MG group and the increased β2-MG group were retrieved, and the results were combined using a fixed effect model and a random effect model. Subgroup analyses were performed based on univariate and multivariate analysis results, and sensitivity analyses were performed to estimate the changes of the combined HRs. In addition, funnel plots and fail-safe numbers were used to estimate publication bias.
RESULTS: A total of 17 qualified publications were included, with a cumulative total of 2,479 cases. The result of heterogeneity examination showed that there was heterogeneity among all studies (P < 0.001, I(2) = 87%). In the random effect model, the combined HR was 2.71 (95% confidence interval [CI]: 1.91-3.85). The result of the total effect examination was statistically significant (Z = 5.59, P < 0.001).
CONCLUSION: The increased β2-MG level was an independent risk factor for the prognosis of NHL.

Entities:  

Keywords:  meta-analysis; non-Hodgkin’s lymphoma; β2-microglobulin

Year:  2015        PMID: 26064301      PMCID: PMC4443135     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  32 in total

1.  The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.

Authors:  E Giné; S Montoto; F Bosch; L Arenillas; S Mercadal; N Villamor; A Martínez; L Colomo; E Campo; E Montserrat; A López-Guillermo
Journal:  Ann Oncol       Date:  2006-08-28       Impact factor: 32.976

2.  Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.

Authors:  Armando López-Guillermo; Luis Colomo; Mónica Jiménez; Francesc Bosch; Neus Villamor; Leonor Arenillas; Ana Muntañola; Silvia Montoto; Eva Giné; Dolors Colomer; Silvia Beà; Elías Campo; Emili Montserrat
Journal:  J Clin Oncol       Date:  2005-02-22       Impact factor: 44.544

3.  Guidelines for NHL: updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia.

Authors:  Andrew D Zelenetz
Journal:  J Natl Compr Canc Netw       Date:  2014-05       Impact factor: 11.908

4.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.

Authors:  S Ibrahim; M Keating; K A Do; S O'Brien; Y O Huh; I Jilani; S Lerner; H M Kantarjian; M Albitar
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

5.  Isolation and properties of a low molecular weight beta-2-globulin occurring in human biological fluids.

Authors:  I Berggård; A G Bearn
Journal:  J Biol Chem       Date:  1968-08-10       Impact factor: 5.157

6.  A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.

Authors:  L Benboubker; C Valat; C Linassier; G Cartron; M Delain; M Bout; F Fetissof; T Lefranq; J P Lamagnere; P Colombat
Journal:  Ann Oncol       Date:  2000-11       Impact factor: 32.976

7.  Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Francis Giles; Farhad Ravandi; Susan Lerner; Hagop Kantarjian; Michael Keating
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

8.  2 -Microglobulin--a free immunoglobulin domain.

Authors:  P A Peterson; B A Cunningham; I Berggård; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-07       Impact factor: 11.205

9.  Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.

Authors:  Wei Xu; Jian-Yong Li; Yu-Jie Wu; Hui Yu; Qiu-Dan Shen; Li Li; Lei Fan; Hong-Xia Qiu
Journal:  Leuk Res       Date:  2007-11-26       Impact factor: 3.156

10.  The small subunit of HL-A antigens is beta 2-microglobulin.

Authors:  H M Grey; R T Kubo; S M Colon; M D Poulik; P Cresswell; T Springer; M Turner; J L Strominger
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  3 in total

1.  Prognostic factors of patients with mycosis fungoides.

Authors:  Anıl Gülsel Bahalı; Ozlem Su; Fatma Pelin Cengiz; Nazan Emiroğlu; Dilek Bıyık Ozkaya; Nahide Onsun
Journal:  Postepy Dermatol Alergol       Date:  2020-11-07       Impact factor: 1.837

2.  Nomograms based on SUVmax of 18F-FDG PET/CT and clinical parameters for predicting progression-free and overall survival in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.

Authors:  Hongyan Li; Guozhu Shao; Yajing Zhang; Xiaomin Chen; Chengcheng Du; Kun Wang; Zairong Gao
Journal:  Cancer Imaging       Date:  2021-01-08       Impact factor: 3.909

3.  Clinicopathologic study of mantle cell lymphoma with epstein-barr virus infection: A case series and literature review.

Authors:  Xiaoju Li; Fanlin Zhou; Shijie Li; Yangyang Wang; Jianing Fan; Xiao Liang; Yan Peng; Yudi Jin; Weiyang Jiang; Fang Liu; Yixing Zhou; Shuke Liu; Tao Wang; Yi Peng; Jianbo Xiong; Jia Liu; Jing Zhang; Changqing He; Hui Zhang; Yu Li
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.